Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 12,698 |
|
|||||
| News | - | ||||||
| Day High | 3.48 | Low High |
|||||
| Day Low | 3.26 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| NexImmune Inc | NEXI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.17 | -4.96% | 3.26 | 17:16:11 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.48 | 3.26 | 3.48 | 3.26 | 3.43 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 140 | 12,698 | $ 3.36 | $ 42,626 | - | 1.2501 - 28.405 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:55:22 | 1 | $ 3.26 | USD |
NexImmune Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 3.52M | 1.06M | - | 0 | -62.51M | -59.07 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
NexImmune News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NEXI Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.43 | 3.89 | 3.01 | 3.44 | 23,056 | -0.17 | -4.96% |
| 1 Month | 5.75 | 5.75 | 3.01 | 4.04 | 38,985 | -2.49 | -43.30% |
| 3 Months | 19.19 | 21.00 | 3.01 | 11.53 | 208,838 | -15.93 | -83.01% |
| 6 Months | 4.15 | 28.405 | 1.2501 | 8.55 | 1,258,235 | -0.89 | -21.45% |
| 1 Year | 9.9675 | 28.405 | 1.2501 | 8.50 | 722,542 | -6.71 | -67.29% |
| 3 Years | 485.25 | 511.75 | 1.2501 | 28.05 | 554,222 | -481.99 | -99.33% |
| 5 Years | 575.25 | 695.00 | 1.2501 | 36.94 | 528,262 | -571.99 | -99.43% |
NexImmune Description
| NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells to generate an immune response that mimics natural biology. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. |
